Clinical trials
Mutation clinical trials
Below are recruiting mutation clinical trials, each written for real people, not researchers. We’re tracking 739 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05253560Recruiting
Study prodromal Parkinson signs in GBA1 mutation carriers
This study looks at early (before full disease) Parkinson-like symptoms in people who carry a specific genetic change called GBA1. It may help researchers understand who could develop Parkinson’s and how early signs can be tracked.
Jerusalem, Please Select...Ages 40–75 - NCT05257967Recruiting
Testing spinal fluid in EGFR-mutant lung cancer with brain covering spread
This trial looks at spinal fluid (also called CSF) in adults with EGFR-mutant lung cancer that has spread to the lining around the brain/spinal cord. The goal is to better understand the disease and what the spinal fluid tests may show to guide care.
Vancouver, British ColumbiaAges 18 years+ - NCT05266846RecruitingPhase 2
Immunotherapy plus anti-angiogenesis and chemo for ALK lung cancer
This Phase 2 trial tests pembrolizumab (an immune therapy), bevacizumab (a medicine that blocks blood-vessel growth), and chemotherapy in people with ALK-rearranged lung cancer that is still present after the first treatment with alectinib. It aims to shrink tumors and improve control of the cancer.
Changsha, HunanAges 18 years+ - NCT05271916RecruitingPhase 1/Phase 2
New targeted drugs for advanced lung cancer with EGFR L858R
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05274048RecruitingPhase 1
Neratinib plus antibody-drug for HER2-positive stomach or esophagus cancer
This early-phase trial tests neratinib together with an antibody-drug to treat advanced HER2-positive gastro-esophageal (stomach/esophagus) cancer that can’t be removed by surgery. It’s for people whose cancer has progressed after at least one HER2-targeted treatment, aiming to shrink tumors and improve outcomes.
Palo Alto, CaliforniaAges 18 years+ - NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05364294Recruiting
Molecular testing for rare inflammatory (autoinflammatory) diseases
This study uses lab testing to better identify the cause of certain rare inflammatory conditions that happen without infection. Finding the cause may help doctors choose more targeted care for you or your child.
ParisAges 1 week–120 years - NCT05378204Recruiting
Testing DNA repair marker for PARP inhibitor resistance
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
BordeauxAges 18 years+ - NCT05379803RecruitingPhase 2
High-dose furmonertinib for lung cancer with brain metastases
This trial tests a high-dose targeted pill, furmonertinib, in people with EGFR-mutated non-small cell lung cancer that has spread to the brain. It aims to better control both the lung cancer and the brain metastases by targeting a specific gene change.
Changsha, HunanAges 18 years+ - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Orange, CaliforniaAges 18 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Orange, CaliforniaAges 12 years+ - NCT05401110RecruitingPhase 1
Osimertinib plus antibody treatment for EGFR-mutated lung cancer
This Phase 1 study tests the combination of osimertinib (a targeted lung cancer pill) with an antibody called carotuximab to treat advanced EGFR-mutated non-small cell lung cancer. It aims to see whether adding the antibody can help when the cancer has grown despite prior EGFR-targeted therapy.
Beverly Hills, CaliforniaAges 18 years+ - NCT05401097RecruitingPhase 2
Venetoclax plus IDH-targeted pills for AML patients who can’t get intensive chemo
This Phase 2 trial tests different ways of using medicines that target IDH mutations (IDH-targeted treatment) plus venetoclax in people newly diagnosed with IDH-mutated AML. It’s designed for patients who cannot safely receive intensive induction chemotherapy, to see which approach works best and is tolerable.
Aurora, ColoradoAges 18 years+ - NCT05424692Recruiting
Test tumor drug sensitivity to guide after-surgery colon cancer care
This study looks at whether testing a small tumor sample can identify which medicines are more likely to work for colorectal cancer after surgery. The results are used to help choose the best “after-surgery” treatment plan, when you have not had chemotherapy before surgery.
Beijing, Beijing MunicipalityAges 18–75 - NCT05436587Recruiting
Genetic testing study for hard-to-classify bone marrow failure
This study looks for gene changes in families affected by rare inherited bone marrow failure that can cause fragile bones and fractures. It may help doctors understand the condition better by linking genetic mutations with family health patterns.
SohagAges Any age - NCT05442060RecruitingPhase 2
Test medicine add-on to erlotinib for EGFR lung cancer
This Phase 2 trial tests whether adding OBI-833/OBI-821 to the standard targeted pill erlotinib works better for some people with EGFR-mutated lung cancer. It may help shrink tumors that already started responding to erlotinib.
Taipei, Beitou DistrictAges 20 years+ - NCT05445791RecruitingPhase 3
Metformin plus targeted lung cancer drugs for EGFR-mutated cancer
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
Mexico CityAges 18 years+ - NCT05446155Recruiting
Studying test results to predict and diagnose melanoma
This study looks at diagnostic and prognostic factors in people who have suspicious pigmented skin lesions or melanoma that doctors are evaluating with surgery or tissue sampling. It may help improve how clinicians decide what the lesion is and what to expect over time.
Helsingborg, Skåne CountyAges 18 years+ - NCT05461664Recruiting
Avapritinib for advanced GIST without PDGFRA exon 18 changes
This trial studies avapritinib, a targeted medicine, for people with advanced or returning gastrointestinal stromal tumors (GIST) whose tumor does not have PDGFRA exon 18 mutations. It aims to see how well the drug can shrink tumors or control the disease.
GuangzhouAges 18 years+ - NCT05469022RecruitingPhase 2
Lazertinib before lung surgery for EGFR-mutant lung cancer
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
SeoulAges 19 years+ - NCT05470504RecruitingPhase 2
Pegvisomant for severe insulin resistance from rare fat or gene problems
This Phase 2 study tests pegvisomant, a medicine that blocks growth hormone, to see if it can improve severe insulin resistance in people with a specific genetic cause or a rare fat distribution condition. If you fit the rare diagnosis, the study may help clarify whether growth-hormone blocking can improve blood sugar and related health markers.
Bethesda, MarylandAges 18–70 - NCT05489549Recruiting
Study of heart amyloid risk in people with TTR gene variants
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
New York, New YorkAges 30–80 - NCT05490472RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors that stopped responding
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
Detroit, MichiganAges 18 years+ - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
La Jolla, CaliforniaAges 18 years+
Hear when a new Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mutation?
- Yes. Clin2 currently lists 739 recruiting mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.